Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
TruSpine Technologies PLC - London-based medical device company - In the financial year ended March 29, pretax loss widens to £941,000, from £651,000 a year ago. Research and development tax credit narrows to £88,000, from £107,000. Development spend for the year widens to £851,000, from £426,000. Consolidated net assets at March 29 fall to £2.6 million, from £2.7 million. The company continues to be in a pre-revenue development phase.
Chief Executive Ian Roberts says: ‘We are a lean and progressive company with a suite of products and IP that have the potential to provide a potential quantum shift in patient treatment within the Spinal Fixation market. The board therefore looks to the future with confidence.’
Current stock price: 3.15 pence
12-month change: down 63%
Copyright 2022 Alliance News Limited. All Rights Reserved.